Cholecystokinin-8 vs Larazotide
Head-to-head comparison of Cholecystokinin-8 (Cholecystokinin (sulfated C-terminal octapeptide, CCK-8)) and Larazotide (Larazotide acetate (AT-1001)) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Cholecystokinin-8 | Larazotide |
|---|---|---|
| Category | Endocrine Peptides | Gastrointestinal |
| Full Name | Cholecystokinin (sulfated C-terminal octapeptide, CCK-8) | Larazotide acetate (AT-1001) |
| Molecular Weight | 1143.2 Da | N/A |
| Half-Life | 1-2 min | short; designed for local gut action |
| Amino Acids | DY(SO3H)MGWMDF-NH2 | 8 |
| Typical Dose | physiologic low-picomolar-nanomolar range|research-dependent | 0.5-4 mg TID (clinical studies) |
| Route | endogenous secretion|research IV/SC | Oral |
| Purity | ≥98% | ≥98% |
| Studies Count | 97 | 40 |
| Research Status | Endogenous | Clinical |
Cholecystokinin-8 Benefits
- ✓gallbladder contraction
- ✓pancreatic enzyme release
- ✓satiety signaling
Larazotide Benefits
- ✓tight-junction-support
- ✓reduced-permeability
- ✓symptom-reduction
- ✓barrier-protection
Cholecystokinin-8 Dosing
physiologic secretion|research-dependent
Larazotide Dosing
0.5-4 mg orally before meals in clinical trials|typically three times daily|short-course or chronic study protocols
Cholecystokinin-8 Side Effects
- ⚠abdominal cramping
- ⚠nausea
- ⚠biliary contraction
Larazotide Side Effects
- ⚠headache
- ⚠nausea
- ⚠abdominal discomfort
Research Overview
Cholecystokinin-8
CCK-8 is a canonical gut hormone fragment with extensive documentation in digestive physiology and appetite control. Sulfation of the tyrosine residue is important for high-affinity receptor activity.
Larazotide
Clinical and translational studies suggest larazotide can reduce antigen passage across the epithelium and improve gut barrier function. It is one of the better-known peptides for intestinal permeability and barrier-focused gastrointestinal therapy.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.